POLARITYTE, INC.
Healthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | |
|---|---|---|---|---|---|---|
| Revenue | $814,000 | $9.4M | $10.1M | $5.7M | $1.6M | $13,000 |
| Operating income | −$22.4M | −$33.7M | −$45.9M | −$93.4M | −$69.4M | −$12.9M |
| Net income | −$7.8M | −$30.2M | −$42.9M | −$92.5M | −$65.4M | −$10.9M |
| Total assets | $22.8M | $31.2M | $45.5M | $53.6M | $80.2M | $20.2M |
| Total liabilities | $6.2M | $11.9M | $18.2M | $14.7M | $8.1M | $15.4M |
| Equity | $16.6M | $19.2M | $27.3M | $38.9M | $72.0M | $170,000 |
| EPS (diluted) | $-1.67 | $-9.43 | $-1.16 | $-3.70 | $-4.86 | $-1.80 |
| Shares out. | 89.5M | 80.3M | 38.4M | 21.5M | 6.9M | 6.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2022- Operating margin
- −2748.5%
- Net margin
- −962.3%
- Return on equity
- −47.1%
- Return on assets
- −34.3%
- Return on capital (ROCE)
- −107.7%
- Liabilities / assets
- 27.3%
- Debt / equity
- 0.37×
- Book value / share
- $0.19
- Revenue growth (YoY)
- −91.3%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2022- Altman Z″ (distress)
- -74.23distress
- Accruals / assets
- 64.6%high accruals
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 5 warning● 1 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- High accruals — earnings-quality risk
- Conservative leverage (liabilities < 50% of assets)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Aug 15, 2023
- NT 10-Kmissed a reporting deadline ↗Jan 30, 2018
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Material events
SEC Form 8-K · most recent- Director / officer change · Amended charter or bylawsAug 18, 2023
- Completed an acquisition or dispositionAug 15, 2023
- Director / officer change · Other material eventAug 1, 2023
- Delisting / listing-standard noticeJul 7, 2023
- Delisting / listing-standard noticeJun 7, 2023
- Entered a material agreement · Bankruptcy or receivership · Regulation FD disclosureJun 7, 2023
- Delisting / listing-standard noticeApr 26, 2023
- Other material eventMar 20, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.